The metastatic prostate cancer market is undergoing a major transition from conventional ADT toward combination-based, biomarker-driven, and precision-targeted treatment approaches. While AR pathway inhibitors continue to dominate across mHSPC and mCRPC settings, the emergence of novel therapies such as 225Ac PSMA 617 (Novartis), 177Lu-DOTA-rosopatamab (TLX591) (Telix Pharmaceuticals), Azetukalner (XEN1101) (Xenon Pharmaceuticals), Mevrometostat (PF-06821497) (Pfizer), Cabozantinib (CABOMETYX, XL184) (Exelixis, Ipsen Pharma, and Takeda), and others is significantly reshaping the treatment paradigm.
The metastatic prostate cancer market is undergoing a major transition from conventional ADT toward combination-based, biomarker-driven, and precision-targeted treatment approaches. While AR pathway inhibitors continue to dominate across mHSPC and mCRPC settings, the emergence of novel therapies such as 225Ac PSMA 617 (Novartis), 177Lu-DOTA-rosopatamab (TLX591) (Telix Pharmaceuticals), Azetukalner (XEN1101) (Xenon Pharmaceuticals), Mevrometostat (PF-06821497) (Pfizer), Cabozantinib (CABOMETYX, XL184) (Exelixis, Ipsen Pharma, and Takeda), and others is significantly reshaping the treatment paradigm.